Roche’s Tecentriq scored some big wins lately, including a pair of first-in-class approvals. But in other cancers, it's decided to pull the plug.

Traditional generics bigwigs Teva, Mylan, Sandoz, Amneal and Endo have lost out to a group of six competitors in terms of U.S. weekly prescriptions.

Pharma’s reputation is holding steady with patient groups with an annual study finding 41% giving pharma good marks, similar to 43% the year before.

WuXi Biologics says its plant in Wuxi, China, has gotten the go-ahead from the FDA to make HIV drug Trogarzo for TaiMed Biologics.

Allergan’s digital booking platform for aesthetic treatments helps consumers find Allergan-branded medical aesthetics but also regular spa services.

United Therapeutics faces allegations of illegally blocking Remodulin generics by teaming with a devicemaker.

As sales of blockbuster lung drug Spiriva flagged in 2018, Boehringer Ingelheim needed a boost from other divisions. Turns out diabetes was the key.

Last July, Roche put a halt on U.S. price hikes. But that didn't stop five of its products from topping analysts' estimates by double digits in Q1.